Story
Novo Nordisk Stock Slides After Berenberg Downgrade Cites Eli Lilly Competition

Shares of Novo Nordisk A/S (NOVOb) declined sharply in Tuesday trading after analysts at Berenberg downgraded the pharmaceutical giant, pointing to a fully realized growth narrative and mounting competitive pressure from rival Eli Lilly.
Berenberg Lowers Rating to 'Hold'
Berenberg lowered its rating on Novo Nordisk to 'Hold' from 'Buy' and reduced its Copenhagen-listed price target to DKK 305 from DKK 325. The move marks a shift from the firm's previously bullish stance on the stock.
According to the analyst note from Kerry Holford, the investment thesis that supported the 'Buy' rating has "fully run its course." Berenberg argued that the expected upside from the oral version of its blockbuster weight-loss drug, Wegovy, has already been factored into the stock's price. The note stated that both the firm and the broader market consensus now forecast approximately DKK 15 billion in 2026 sales for the Wegovy pill, leaving little room for positive surprises.
Intensifying Competition from Eli Lilly
The downgrade centered on the growing competitive threat posed by U.S. rival Eli Lilly in the lucrative GLP-1 drug market. Berenberg's analysis suggested that Lilly is positioned to benefit disproportionately as U.S. Medicare begins providing access to weight-loss medications.
AdAdding to the competitive headwinds, Berenberg flagged the imminent FDA approval of Lilly’s oral diabetes pill, which is expected to amplify its direct-to-consumer advertising and further challenge Novo Nordisk’s market share. The competitive narrative was reinforced by the UK's regulatory approval of Lilly's Foundayo pill on Tuesday.
Market Reaction
In response to the downgrade, Novo Nordisk shares fell 3.4% to trade at DKK 296.7 during the session. The stock's weakness was specific to the company, as broader U.S. equity benchmarks like the S&P 500 and Nasdaq were trading higher.
The analyst action comes just days after a mixed market reaction to Novo Nordisk's second-quarter earnings, suggesting investors are reassessing the stock's near-term upside amid the shifting competitive landscape.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.